Nutex Health, Inc.
NUTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.03 | 0.01 | 5.07 |
| FCF Yield | 12.90% | -6.92% | 2.99% | 0.57% |
| EV / EBITDA | 3.08 | -25.57 | -3.65 | 132.19 |
| Quality | ||||
| ROIC | 20.91% | -7.90% | -105.35% | 45.74% |
| Gross Margin | 40.89% | 14.04% | 7.03% | 54.08% |
| Cash Conversion Ratio | 0.24 | -0.03 | -0.12 | 1.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 29.83% | -9.27% | -7.16% | 50.60% |
| Free Cash Flow Growth | 353.02% | -122.91% | -73.65% | 435.67% |
| Safety | ||||
| Net Debt / EBITDA | 2.00 | -17.40 | -0.59 | 0.78 |
| Interest Coverage | 6.55 | -1.95 | -32.55 | 27.48 |
| Efficiency | ||||
| Inventory Turnover | 99.55 | 62.78 | 57.70 | 54.10 |
| Cash Conversion Cycle | 165.22 | 54.99 | 60.55 | 90.77 |